Presynaptic G-protein-coupled receptors dynamically modify vesicle fusion, synaptic cleft glutamate concentrations, and motor behavior.
Understanding how neuromodulators regulate behavior requires investigating their effects on functional neural systems, but also their underlying cellular mechanisms. Utilizing extensively characterized lamprey motor circuits, and the unique access to reticulospinal presynaptic terminals in the intact spinal cord that initiate these behaviors, we investigated effects of presynaptic G-protein-coupled receptors on locomotion from the systems level, to the molecular control of vesicle fusion. 5-HT inhibits neurotransmitter release via a Gbetagamma interaction with the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex that promotes kiss-and-run vesicle fusion. In the lamprey spinal cord, we demonstrate that, although presynaptic 5-HT receptors inhibit evoked neurotransmitter release from reticulospinal command neurons, their activation does not abolish locomotion but rather modulates locomotor rhythms. Liberation of presynaptic Gbetagamma causes substantial inhibition of AMPA receptor-mediated synaptic responses but leaves NMDA receptor-mediated components of neurotransmission mostly intact. Because Gbetagamma binding to the SNARE complex is displaced by Ca(2+)-synaptotagmin binding, 5-HT-mediated inhibition displays Ca(2+) sensitivity. We show that, as Ca(2+) accumulates presynaptically during physiological bouts of activity, 5-HT/Gbetagamma-mediated presynaptic inhibition is relieved, leading to a frequency-dependent increase in synaptic concentrations of glutamate. This frequency-dependent phenomenon mirrors a shift in the vesicle fusion mode and a recovery of AMPA receptor-mediated EPSCs from inhibition without a modification of NMDA receptor EPSCs. We conclude that activation of presynaptic 5-HT G-protein-coupled receptors state-dependently alters vesicle fusion properties to shift the weight of NMDA versus AMPA receptor-mediated responses at excitatory synapses. We have therefore identified a novel mechanism in which modification of vesicle fusion modes may profoundly alter locomotor behavior.
Gerachshenko
Tatyana
T
Department of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.
Schwartz
Eric
E
Bleckert
Adam
A
Photowala
Huzefa
H
Seymour
Andrew
A
Alford
Simon
S
D000818:Animals; D004305:Dose-Response Relationship, Drug; D018698:Glutamic Acid / Q000378:metabolism*; D007798:Lampreys; D008561:Membrane Fusion / Q000187:drug effects / Q000502:physiology*; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D017729:Presynaptic Terminals / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology; D013569:Synapses / Q000187:drug effects / Q000502:physiology; D055366:Synaptic Potentials / Q000187:drug effects / Q000502:physiology; D013572:Synaptic Vesicles / Q000187:drug effects / Q000502:physiology*
D012701:Serotonin; D018698:Glutamic Acid
J Comput Neurosci. 2001 Sep-Oct;11(2):183-200
11717534
Brain Res. 1990 Jan 8;506(2):297-302
1967966
Science. 1992 Nov 27;258(5087):1498-501
1359647
J Comp Neurol. 1985 Apr 22;234(4):501-22
2859306
J Neurophysiol. 2005 Aug;94(2):1392-404
15872068
J Neurosci. 1991 Jun;11(6):1496-507
1675264
Science. 1987 Apr 17;236(4799):312-4
3563512
Brain Res. 1985 Jan 28;325(1-2):302-6
2858251
J Neurophysiol. 2005 Feb;93(2):980-8
15456802
Acta Physiol Scand. 1973 Mar;87(3):320-33
4348892
Nat Neurosci. 2005 May;8(5):597-605
15834421
J Physiol. 1989 Jul;414:265-82
2607432
Nat Neurosci. 2008 Dec;11(12):1419-29
18997790
Brain Res Rev. 2008 Jan;57(1):183-91
17928060
Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17843-8
17968015
Brain Res. 1985 Jun 17;336(2):390-5
2988706
J Neurophysiol. 1993 Aug;70(2):695-709
8105036
Neurosci Lett. 1991 Jan 14;122(1):71-44
1676146
Science. 1992 Oct 23;258(5082):662-5
1411575
Prog Brain Res. 1989;80:321-7; discussion 315-9
2699371
J Neurophysiol. 2003 Sep;90(3):1714-27
12736238
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4281-6
16537522
J Neurosci. 2006 Mar 15;26(11):3030-6
16540581
J Neurophysiol. 1999 Apr;81(4):1513-30
10200188
Nature. 2007 Mar 29;446(7135):567-71
17392788
J Neurophysiol. 2006 Aug;96(2):931-5
16707720
Nat Neurosci. 2005 Apr;8(4):421-5
15778713
Neuron. 2006 Jan 19;49(2):243-56
16423698
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20576-81
18077369
Mol Pharmacol. 2007 Nov;72(5):1210-9
17715396
Brain Res. 1987 Apr 7;408(1-2):321-5
2885068
J Neurophysiol. 2006 Mar;95(3):1545-55
16338993
J Physiol. 2001 Apr 15;532(Pt 2):323-36
11306653
J Neurosci. 2007 May 30;27(22):5857-68
17537956
Brain Res Rev. 2008 Jan;57(1):172-82
17916380
Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):695-705
12740115
Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):328-34
9303569
J Neurosci. 1999 Mar 1;19(5):1647-56
10024351
Science. 2001 Apr 13;292(5515):293-7
11303105
Neurosci Lett. 1989 May 22;100(1-3):188-92
2668801
Brain Res. 1989 Apr 10;484(1-2):203-16
2713681
J Physiol. 1984 Feb;347:225-39
6142945
Nature. 1995 Mar 16;374(6519):266-8
7885446
Brain Res. 1986 Aug 20;380(2):244-52
2428424
Eur J Neurosci. 2007 Sep;26(5):1205-12
17767499
Nature. 2006 Nov 2;444(7115):102-5
17065984
Neuron. 1999 Dec;24(4):809-17
10624945
Pharmacol Rev. 2006 Dec;58(4):837-62
17132857
Electroencephalogr Clin Neurophysiol. 1969 May;26(5):549
4181500
J Neurosci. 2005 Aug 31;25(35):7993-9
16135756
Science. 2009 Mar 13;323(5920):1448-53
19213879
J Neurosci. 2001 Oct 1;21(19):7793-803
11567070
Eur J Neurosci. 2000 Nov;12(11):4081-92
11069605
J Exp Biol. 1985 May;116:27-46
4056654